27 results on '"Bradley, Terrence J."'
Search Results
2. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
3. Leveraging Hypomethylating Agents for Better MDS Therapy
4. Data from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
5. Table S8 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
6. Supplementary Legend from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
7. Figure S4 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
8. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
9. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations
10. Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
11. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
12. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
13. Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms
14. Molecular annotation of extramedullary acute myeloid leukemia to identify prevalence of targetable mutations.
15. Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
16. Real World Outcomes of Liposomal Daunorubicin and Cytarabine Versus 7+3 in Patients with Secondary Acute Myeloid Leukemia
17. A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2mutant AML
18. Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience
19. A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia
20. Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition
21. Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
22. A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
23. The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS
24. Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia
25. Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature
26. Mutational Frequency in Hispanic and Non-Hispanic Patients with Acute Myeloid Leukemia (AML): Updated Analysis of 227 Patients
27. Increased Frequency of IDH1/2Mutations in Extramedullary Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.